["{\n\"step_by_step_thinking\": \"The relevant documents discuss mycosis fungoides, a low-grade malignant cutaneous T-cell lymphoma. The document 'Cutaneous T-cell lymphoma' proposes the use of the designation 'cutaneous T-cell lymphoma, with or without leukemic phase'. This suggests that mycosis fungoides is part of the broader category of cutaneous T-cell lymphomas. Mogamulizumab is a monoclonal antibody therapy discussed in 'Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas' as a treatment option for non-Hodgkin's lymphomas. Cutaneous T-cell lymphoma, including mycosis fungoides, falls under the category of non-Hodgkin's lymphomas. Therefore, mogamulizumab can be used to treat cutaneous T-cell lymphoma.\",\n\"answer_choice\": \"A\"\n}"]